Farmak International Delivered Vasopressin to Qatar in Its First Export to the Market
In June 2025, Farmak International delivered vasopressin to Qatar in its first-ever export to the country, following a successful tender award.
The product was supplied in accordance with local regulatory requirements and global GMP standards.
Vasopressin is an essential medicine indicated for the treatment of diabetes insipidus and bleeding from enlarged veins in the oesophagus (food pipe). The product was supplied in ampoules, manufactured at Farmak Group’s own production facilities, which operate under EU GMP certification.
This delivery marks Farmak International’s entry into the Qatari market and supports its broader strategy to expand access to hospital and critical care medicines. During the first half of 2025, the company entered three new markets in the Middle East and Africa, reinforcing its operational footprint across the region.
About Farmak International
Farmak International, a brand managed by FARMAK AG, headquartered in Switzerland, leads the Farmak Group’s global strategy, overseeing business operations, asset management, and expansion into international markets. It oversees and manages the entities established to conduct business under the Farmak International brand in Switzerland, Spain, Poland, the Czech Republic, Slovakia, the United Kingdom, the UAE, and by representative office in Vietnam.
